DexCom, Inc. Q2 2026 Earnings Recap

DexCom's shares gained 11.1% following Q2 earnings as strong product demand, consistent new customer growth, and positive clinical trial results for non-insulin type 2 diabetes patients clearly outpaced concerns. Investors appear encouraged by solid revenue growth and broadening commercial coverage despite limited detail on potential margin pressures or segment weaknesses. Key Takeaways:

Key Takeaways

• Reported 13% year-over-year revenue growth, with 12% organic growth, driven by broad global demand for DexCom CGM systems.
• New customer starts remained at record levels, including a sequential increase in the US market.
• Positive clinical trial results (Connect study) demonstrated a 1.6% A1C improvement in type 2 diabetes patients not on insulin, supporting reimbursement expansion.
• Coverage now includes more than 7 million non-insulin type 2 diabetes patients across major US commercial PBMs.
• Announced a $1 billion share repurchase plan for 2026, signaling confidence in capital allocation and underlying business stability.